# SpyGlass Pharma Reports Sustained 4-Year Results for BIM-IOL System

- URL: https://stocks.freetheai.org/news/spyglass-pharma-reports-sustained-4-year-results-for-bim-iol-system-f61656
- Published: 2026-10-19T20:13:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:SGP](https://stocks.freetheai.org/symbols/NASDAQ-SGP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

SpyGlass Pharma, Inc. (SGP) reported positive four-year first-in-human clinical trial results for its BIM-IOL System. Across all dose groups, intraocular pressure dropped by a mean of 37%, moving from 25.1 mmHg at baseline to 15.9 mmHg at 48 months. Shares of the company rose 2.50% to $24.60 following the update.

The four-year findings highlight durable eye pressure control without daily topical medication. Among 21 evaluable patients, 86% stayed entirely off drops at 48 months. In addition, 90% of participants preserved visual acuity of 20/25 or better, and the study recorded no product-related adverse events through four years.

The initial first-in-human trial is designed to track participants over a total seven-year follow-up period. Meanwhile, the company is actively advancing enrollment in its Phase 3 clinical trial.

## Key points

- SpyGlass Pharma's BIM-IOL System achieved a 37% mean reduction in intraocular pressure over four years.
- At 48 months, 86% of evaluable patients remained completely off topical eye drops.
- No product-related adverse events were reported, and 90% of patients maintained visual acuity of 20/25 or better.
- The first-in-human trial will continue for seven years as Phase 3 enrollment progresses.

## Questions and answers

### What were the 4-year trial results for SpyGlass Pharma?

The BIM-IOL System sustained a 37% mean reduction in eye pressure at 48 months, with 86% of evaluable patients off topical drops and zero product-related adverse events.

### Is SpyGlass Pharma currently enrolling Phase 3 trials?

Yes, the company is actively enrolling patients in its Phase 3 trial while continuing to monitor initial study participants through a full seven-year follow-up period.